Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Importance Of Monitoring And Early Switch To Second Generation Tyrosine Kinase Inhibitors For The Prognosis Of Patients With Chronic Myeloid Leukemia With Imatinib Resistance Or Intolerance|
Braga Jr J.W.R.
do Carmo Rego M.A.
de Souza C.A.
|Abstract:||Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.